Nephrocare Health Services Ltd
NEPHROPLUS NSE
Nephrocare Health Services Ltd
Healthcare ServicesNSE: NEPHROPLUS BSE: 544647 Healthcare Service Provider
Key Fundamentals
MicrocapHealthcare Service ProviderHealthcare ServicesMarket Cap
₹6,909 Cr
Volatility
Moderate
P/E Ratio
5.77
EBITDA
₹252 Cr
Return on Equity
6.88%
Debt to Equity
0.07
Book Value
₹111.03
52W High
₹769.75
52W Low
₹446
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nephrocare Health Services Ltd insights
36 extracted metrics + investor summaries across FY21–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 162% CAGR over last 5 years
Weaknesses
4- Stock is trading at 6.24 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.2% over last 3 years.
- Company's cost of borrowing seems high
Growth Rate
Revenue Growth
32.93% ↗
Net Income Growth
14.46% ↗
Cash Flow Change
71.84% ↗
ROE
-40.12% ↘
ROCE
-11.39% ↗
EBITDA Margin (Avg.)
4.64% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 8d agoAI opinion · based on fundamentals
Risk high
Nephrocare Health Services (NephroPlus) is a healthcare services company with a market cap of ₹6,798 Cr trading at a PE of 89.4x. The company has delivered strong revenue growth of 32% CAGR over 3 years and profit growth of 162% CAGR over 5 years, but carries a relatively low ROE of ~10% over 3 years and trades at 6.15x book value with zero dividend payout.
Bull Case 7
- Exceptional profit growth of 162% CAGR over the last 5 years indicates strong operating leverage and scalability in the dialysis services business
- Consistent revenue growth of 32% CAGR over 3 years and 28% over 5 years demonstrates sustained demand for nephrology services
- Company is almost debt-free, significantly reducing financial risk and interest burden on the balance sheet
- Active debt reduction demonstrates disciplined capital allocation and strengthening of the balance sheet over time
- TTM sales growth of 32% shows continued momentum in the most recent period with no signs of deceleration from the 3-year trend
- Operating in the chronic kidney disease treatment space which has structural tailwinds from rising diabetes and hypertension prevalence in India
- TTM profit growth of 12% shows the company remains profitable and growing even as it scales, though at a slower pace than historical averages
Bear Case 8
- PE ratio of 89.4x is extremely elevated, pricing in significant future growth and leaving little margin of safety if execution falters
- 3-year average ROE of only 10% is modest for a company trading at such premium valuations, suggesting capital is not being deployed efficiently enough to justify the price
- Zero dividend yield despite repeated profitability indicates shareholders receive no income return, with all value dependent on capital appreciation
- Price-to-book ratio of 6.15x means investors are paying a steep premium over the company's net asset value
- TTM profit growth has decelerated sharply to 12% compared to 103% CAGR over 3 years, suggesting growth normalization or margin pressure
- Company's cost of borrowing appears high, which could erode returns if any future debt is taken on for expansion
- Last year ROE of 9% is below the 3-year average of 10%, indicating a declining trend in return on equity rather than improvement
- With no stock CAGR data available across any time period, there is limited price history transparency for investors to assess historical shareholder returns
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 6d ago Neutral 3
- Rs 70 Cr block trade executed Jul 9
A block trade worth Rs 70 crore was executed on NSE/BSE for approximately 11 lakh shares at Rs 636.36 per share, indicating significant large-scale institutional activity.
- Q1FY27 earnings call Aug 12 Jul 24
Nephrocare has scheduled its Q1FY27 earnings conference call for August 12, 2026 to discuss unaudited standalone and consolidated results for the quarter ended June 30, 2026.
- 17th AGM on Aug 12 Jul 17
Nephrocare will hold its 17th AGM on August 12, 2026 via video conferencing, with remote e-voting open from August 8 to August 11.
TL;DR: A quiet period for Nephrocare Health Services with no material positive or negative catalysts. The Rs 70 crore block trade suggests institutional interest but direction is unclear without knowing buyer/seller intent. Investors should watch the Q1FY27 results on Aug 12 for growth trajectory and margin trends in the dialysis services business.
Quarterly Results
| Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 197 | 219 | 246 | 260 | 266 |
| Expenses | 153 | 168 | 182 | 199 | 215 |
| Operating Profit | 44 | 51 | 64 | 61 | 51 |
| OPM % | 22% | 23% | 26% | 23% | 19% |
| Other Income | 5 | 4 | 4 | 3 | 12 |
| Interest | 5 | 6 | 45 | 6 | 3 |
| Depreciation | 18 | 19 | 23 | 22 | 26 |
| PBT | 26 | 30 | -1 | 36 | 33 |
| Tax % | 24% | 17% | 1427% | 11% | 9% |
| Net Profit | 20 | 25 | -9 | 32 | 30 |
| EPS in Rs | 96.5 | 119 | -5.24 | 3.21 | 3.03 |
Profit & Loss
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 286 | 318 | 437 | 566 | 756 | 999 |
| Expenses | 248 | 302 | 389 | 465 | 589 | 774 |
| Operating Profit | 37 | 16 | 49 | 101 | 167 | 225 |
| OPM % | 13% | 5% | 11% | 18% | 22% | 23% |
| Other Income | 5 | 10 | 6 | 8 | 14 | 23 |
| Interest | 7 | 10 | 16 | 20 | 21 | 60 |
| Depreciation | 34 | 42 | 47 | 56 | 72 | 91 |
| PBT | 1 | -27 | -9 | 33 | 87 | 97 |
| Tax % | 31% | -21% | 37% | -6% | 23% | 21% |
| Net Profit | 1 | -21 | -12 | 35 | 67 | 77 |
| EPS in Rs | 3.4 | -107 | -58.69 | 170 | 322 | 7.66 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 20 |
| Reserves | 245 | 391 | 384 | 409 | 579 | 1,096 |
| Borrowings | 140 | 119 | 200 | 271 | 261 | 80 |
| Other Liabilities | 42 | 59 | 81 | 124 | 153 | 271 |
| Total Liabilities | 428 | 571 | 666 | 806 | 994 | 1,467 |
| Fixed Assets | 192 | 205 | 239 | 356 | 396 | 517 |
| CWIP | 2 | 43 | 34 | 1 | 6 | 6 |
| Investments | 0 | 0 | 0 | 0 | 51 | 178 |
| Other Assets | 234 | 322 | 393 | 449 | 542 | 767 |
| Total Assets | 428 | 571 | 666 | 806 | 994 | 1,467 |
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Operating | 32 | 14 | 11 | 72 | 135 | 233 |
| Investing | -62 | -130 | -76 | -52 | -125 | -392 |
| Financing | 36 | 121 | 60 | 27 | 54 | 157 |
| Net Cash Flow | 5 | 6 | -4 | 47 | 65 | -2 |
| Free Cash Flow | -29 | -64 | -62 | -8 | 35 | 113 |
| CFO/OP | 49 | 119 | 14 | 80 | 82 | 116 |
Ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 101 | 123 | 132 | 131 | 129 | 116 |
| Inventory Days | 65 | 50 | 67 | — | — | — |
| Days Payable | 56 | 70 | 63 | — | — | — |
| Cash Conversion Cycle | 110 | 103 | 137 | 131 | 129 | 116 |
| Working Capital Days | 26 | 55 | 19 | 56 | 27 | 42 |
| ROCE % | — | -4% | 1% | 8% | 14% | 15% |
Documents
5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
10 Apr - Regulation 74(5) certificate filed for quarter ended March 31, 2026. 10 Apr - Regulation 74(5) certificate filed for quarter ended March 31, 2026.
Frequently Asked Questions about Nephrocare Health Services Ltd
What does Nephrocare Health Services Ltd do?
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]
Where is Nephrocare Health Services Ltd (NEPHROPLUS) listed?
Nephrocare Health Services Ltd is listed on the Indian stock exchanges. It is listed on NSE: NEPHROPLUS and BSE: 544647. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Nephrocare Health Services Ltd belong to?
Nephrocare Health Services Ltd operates in the Healthcare Services sector within the Healthcare Service Provider industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Nephrocare Health Services Ltd?
Nephrocare Health Services Ltd has a market capitalisation of approximately ₹6909.46 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Nephrocare Health Services Ltd?
The Price-to-Earnings (PE) ratio of Nephrocare Health Services Ltd is 5.77. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Nephrocare Health Services Ltd?
Over the past 52 weeks, Nephrocare Health Services Ltd has traded between a low of ₹446 and a high of ₹769.75. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Nephrocare Health Services Ltd?
Nephrocare Health Services Ltd has a Return on Equity (ROE) of 6.88%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Nephrocare Health Services Ltd on Tapetide?
On Tapetide, you can view Nephrocare Health Services Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]